Johnson & Johnson Private Limited: Clinical Trials

6 completed, 1 active not recruiting, 1 recruiting, 1 withdrawn. 6 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	6	Completed 4, Active not recruiting 1, Recruiting 1

Follow Johnson & Johnson Private Limited: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) Guselkumab - Arthritis, Psoriatic	Phase 4	Recruiting	Johnson & Johnson Private Limited	100	2025-08-12	2026-08-28
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma Teclistamab - Multiple Myeloma	Phase 4	Active not recruiting	Johnson & Johnson Private Limited	75	2025-05-22	2026-09-25
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes Canagliflozin + Metformin hydrochloride (Fixed Dose Combination) - Diabetes Mellitus	Phase 4	Completed	Johnson & Johnson Private Limited	276	2020-11-25	2025-03-30
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Ibrutinib 420 mg, Ibrutinib 560 mg - Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell	Phase 4	Completed	Johnson & Johnson Private Limited	75	2019-06-26	2025-05-25
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Daratumumab - Multiple Myeloma	Phase 4	Completed	Johnson & Johnson Private Limited	150	2019-06-10	2025-02-03
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Golimumab - Spondylitis, Ankylosing, Arthritis, Psoriatic	Phase 4	Completed	Johnson & Johnson Private Limited	100	2019-01-07	2025-02-04
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting Canagliflozin 300 mg - Diabetes Mellitus, Type 2		Completed	Johnson & Johnson Private Limited	178	2018-09-05	2020-08-19
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India Ibrutinib - Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell		Completed	Johnson & Johnson Private Limited	40	2018-04-28	2025-02-03
A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer Abiraterone Acetate - Prostate Cancer		Withdrawn	Johnson & Johnson Private Limited		2016-05-31	2025-02-03

Conditions studied

Arthritis, Psoriatic (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Multiple Myeloma (2)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Prostatic Neoplasms (1)  ·  Spondylitis, Ankylosing (1)

Interventions

Canagliflozin (2)  ·  ibrutinib (2)  ·  Abiraterone Acetate (1)  ·  Metformin (1)  ·  daratumumab (1)  ·  golimumab (1)  ·  guselkumab (1)

Countries

India (9)

Results publications

PMID 38116642, PMID 39971605